Insider trade

Immuneering (IMRX): Director received 33K units

Peter Feinberg, Director at Immuneering, reported a grant / award of 33K units.

33K
Derivative units
Traded
Jun 11, 2026
Filed
Jun 11, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. May 15, 2026Company filing · Form 8-K · ResultsReported its results
  2. Jun 11, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On June 11, 2026, the Board of Directors (the “Board”) of Immuneering Corporation (the “Company”) appointed Andrew Gengos as th e Chief Financial Officer and Treasurer of t he Company, to become effective on the commencement of his employment with the Company, which is expected to be on or before July 16, 2026 (the date Mr. Gengos actually commences employment with the Company, the “Effective Date”).”

What came next

  1. Jun 15, 2026Insider · Their largest buy since 2021Officer purchased ~$25K of IMRX shares in the open market
  2. Jun 23, 2026InsiderCEO purchased ~$11K of IMRX shares in the open market
  3. Aug 5, 2026Company filing · Form 8-K · ResultsReported its results
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Immuneering

For Immuneering, OQRO holds 1 insider filing (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its IMRX page.

Other recent filings by Peter Feinberg, Director

The full history of Peter Feinberg, Director is on the profile page.

How this filing works

Explore the data

Common questions

Which Immuneering (IMRX) insider traded, and how much?

Peter Feinberg, Director at Immuneering, reported a grant / award of 33K units. Not an open-market trade.

When did it happen, and when was it made public?

Traded: Jun 11, 2026. Filed: Jun 11, 2026.

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Immuneering recently?

For Immuneering, OQRO holds 1 insider filing (SEC Form 4 or Form 144) dated in the last 90 days. They are listed on the IMRX page.

Does this mean IMRX stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Immuneering

Everything OQRO holds on this company is on its IMRX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data